Jie Li , Hanhui Li , Xiaoping Tan , Jun Zhang , Shengqi Du , Yueyue Lu , Qing Zhang
{"title":"The predictive value of serum mRNA-RGS10 for the severity and prognosis of acute pancreatitis","authors":"Jie Li , Hanhui Li , Xiaoping Tan , Jun Zhang , Shengqi Du , Yueyue Lu , Qing Zhang","doi":"10.1016/j.cca.2025.120531","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>The study investigates serum RGS10 expression in acute pancreatitis (AP) patients and its prognostic value.</div></div><div><h3>Methods</h3><div>Serum samples and clinical data were collected from 104 AP patients and 34 healthy controls (HC). Whole transcriptome sequencing was performed on serum samples from three randomly selected individuals per group.</div></div><div><h3>Results</h3><div>Serum RGS10 levels were significantly higher in the moderately severe acute pancreatitis (MSAP) group compared to the mild acute pancreatitis (MAP) and HC (P < 0.01). RGS10 expression was positively correlated with BISAP score, CTSI, INR, PCT, BUN, and Cr. Univariate and multivariate regression analyses identified RGS10, hydrothorax, and Ca<sup>2+</sup> as independent risk factors for MSAP. RGS10 demonstrated the highest predictive accuracy for MSAP, with an accuracy of 80.0 %, sensitivity of 78.0 %, specificity of 74.1 %. Combining these indicators enhanced the predictive efficacy, achieving an accuracy of 91.2 %, sensitivity of 92.7 %, specificity of 76.3 %. Follow-up data indicated that RGS10, Cr, D-dimer, CTSI, PTAR, PLR, BUN, PT, INR, and disease severity were risk factors for recurrence AP.</div></div><div><h3>Conclusions</h3><div>RGS10 may serve as a novel biomarker for AP severity and recurrence risk.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"578 ","pages":"Article 120531"},"PeriodicalIF":2.9000,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125004103","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives
The study investigates serum RGS10 expression in acute pancreatitis (AP) patients and its prognostic value.
Methods
Serum samples and clinical data were collected from 104 AP patients and 34 healthy controls (HC). Whole transcriptome sequencing was performed on serum samples from three randomly selected individuals per group.
Results
Serum RGS10 levels were significantly higher in the moderately severe acute pancreatitis (MSAP) group compared to the mild acute pancreatitis (MAP) and HC (P < 0.01). RGS10 expression was positively correlated with BISAP score, CTSI, INR, PCT, BUN, and Cr. Univariate and multivariate regression analyses identified RGS10, hydrothorax, and Ca2+ as independent risk factors for MSAP. RGS10 demonstrated the highest predictive accuracy for MSAP, with an accuracy of 80.0 %, sensitivity of 78.0 %, specificity of 74.1 %. Combining these indicators enhanced the predictive efficacy, achieving an accuracy of 91.2 %, sensitivity of 92.7 %, specificity of 76.3 %. Follow-up data indicated that RGS10, Cr, D-dimer, CTSI, PTAR, PLR, BUN, PT, INR, and disease severity were risk factors for recurrence AP.
Conclusions
RGS10 may serve as a novel biomarker for AP severity and recurrence risk.
期刊介绍:
The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells.
The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.